论文部分内容阅读
目的探讨单羧酸转运蛋白-1(monocarboxylate transporter-1,MCT1)和CD147在不同级别人脑胶质瘤中的表达情况及其与胶质瘤预后的关系。方法采用免疫组化S-P法检测MCT1和CD147在28例低级别胶质瘤和32例高级别胶质瘤中的表达情况;建立前瞻性队列随访观察上述胶质瘤患者术后情况,使用生存曲线和COX多因素模型进行生存预后分析。结果MCT1和CD147在人脑胶质瘤中均有高表达;在高级别胶质瘤中,两者的阳性表达率(93.8%、90.6%)和强阳性表达率(73.3%、72.4%)显著高于低级别组(两者的阳性表达率为46.4%、50%,强阳性表达率为30.8%、35.7%,P<0.01,P<0.05),且两者表达呈正相关(r=0.671,P<0.05);MCT1和CD147表达相关生存曲线差异有统计学意义(P=0.021,P=0.001),COX分析CD147高表达对胶质瘤患者的术后生存预后具有明显影响(P=0.017)。结论MCT1和CD147与胶质瘤恶性程度有密切关系,两者的表达,尤其是CD147可作为胶质瘤预后判断的参考指标和治疗靶点。
Objective To investigate the expression of monocarboxylate transporter-1 (MCT1) and CD147 in human gliomas of different grades and its relationship with the prognosis of gliomas. Methods Immunohistochemical SP method was used to detect the expression of MCT1 and CD147 in 28 cases of low grade gliomas and 32 cases of high grade gliomas. The prospective cohort was established to observe the postoperative survival of the glioma patients. Survival curve And COX multifactorial model for survival and prognosis. Results The positive expression rate of MCT1 and CD147 in human glioma was high (93.8%, 90.6%) and strong positive expression rate (73.3%, 72.4%) in high grade gliomas (P <0.01, P <0.05). There was a positive correlation between the two expression levels (r = 0.671, P < (P = 0.021, P = 0.001). COX analysis of CD147 overexpression had a significant effect on the prognosis of patients with glioma (P = 0.017) . Conclusion MCT1 and CD147 are closely related to the malignant degree of glioma. The expression of both, especially CD147, may serve as a reference and therapeutic target for the prognosis of gliomas.